Product Information
LAMOTRIGINE ER 300 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.2596 per EA under NDC 68382098406. Its NADAC has been published 167 times since Jul 26, 2023.
FDA first approved this application on Apr 1, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382098406
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMOTRIGINEApproval Type
Generic (ANDA)
FDA Application
ANDA207763FDA Approved
4/1/2020
TE Code
AB
On Market Since
5/14/2020
Pharmacological Classes
Price Statistics
The NADAC for LAMOTRIGINE ER 300 MG TABLET has been published 167 times since Jul 26, 2023, and over the history we have for it it has declined 41.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2596 per EA |
|---|---|
| All-time high | $2.5999 (Feb 14, 2024) |
| All-time low | $0.9867 (Nov 20, 2024) |
| 52-week high | $1.4630 |
| 52-week low | $1.1920 |
| Median price | $1.3651 |
| Average price | $1.5697 |
| Largest weekly change | +59.8% (Jun 19, 2024) |
| Weeks tracked | 167 |
| Tracking since | Jul 26, 2023 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamotrigine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMOTRIGINE ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMOTRIGINE ER 300 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.2596 per EA (NDC 68382098406), effective Sep 30, 2026.
How has the price of LAMOTRIGINE ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMOTRIGINE ER 300 MG TABLET has declined 41.9%. It has been tracked across 167 weekly CMS publications since Jul 26, 2023.
What are the highest and lowest recorded NADAC prices for LAMOTRIGINE ER 300 MG TABLET?
Since Jul 26, 2023, the NADAC for LAMOTRIGINE ER 300 MG TABLET has ranged from a low of $0.9867 (Nov 20, 2024) to a high of $2.5999 (Feb 14, 2024), with a median of $1.3651 per EA.
Are there cheaper alternatives to LAMOTRIGINE ER 300 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LAMOTRIGINE ER 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LAMOTRIGINE ER 300 MG TABLET?
LAMOTRIGINE ER 300 MG TABLET (NDC 68382098406) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.